ConvergeCELL: An end-to-end platform from patient transcriptomics to therapeutic hypotheses

preprint OA: closed
Full text JSON View at publisher

Abstract

Translating transcriptomic data into therapeutic hypotheses remains fragmented and labor-intensive. Here we present ConvergeCELL, a platform combining a patient representation model trained on over 20 million cells across 4,479 patients, an interpretability framework for gene discovery, and a large language model-driven workflow that classifies candidates along an evidence hierarchy and constructs mechanism-of-action hypotheses. Validated on held-out cohorts spanning lupus, multiple myeloma, and sepsis across single-cell and bulk modalities, ConvergeCELL recovers known disease-associated genes at or above differential expression, machine-learning, and patient-level foundation model (PaSCient) baselines. The advantage is most pronounced for clinically validated, disease-specific drug targets: ConvergeCELL ranks TNFSF13B (Belimumab; lupus), TNFRSF17/BCMA (Belantamab; myeloma), and CXCR4 (Plerixafor; myeloma) within the top 0.3% of its gene rankings - significantly outcompeting alternative approaches. ConvergeCELL delivers an end-to-end translational workflow with state-of-the-art performance on both disease-associated gene recovery and patient-level disease classification. The pretrained ConvergeCELL patient representation model and bulk distillation module are publicly available on Hugging Face (huggingface.co/ConvergeBio/virtual-cell-patient) under the Apache 2.0 license.
Full text 2,208 characters · extracted from oa-doi-fallback · click to expand
Abstract Translating transcriptomic data into therapeutic hypotheses remains fragmented and labor-intensive. Here we present ConvergeCELL, a platform combining a patient representation model trained on over 20 million cells across 4,479 patients, an interpretability framework for gene discovery, and a large language model-driven workflow that classifies candidates along an evidence hierarchy and constructs mechanism-of-action hypotheses. Validated on held-out cohorts spanning lupus, multiple myeloma, and sepsis across single-cell and bulk modalities, ConvergeCELL recovers known disease-associated genes at or above differential expression, machine-learning, and patient-level foundation model (PaSCient) baselines. The advantage is most pronounced for clinically validated, disease-specific drug targets: ConvergeCELL ranks TNFSF13B (Belimumab; lupus), TNFRSF17/BCMA (Belantamab; myeloma), and CXCR4 (Plerixafor; myeloma) within the top 0.3% of its gene rankings - significantly outcompeting alternative approaches. ConvergeCELL delivers an end-to-end translational workflow with state-of-the-art performance on both disease-associated gene recovery and patient-level disease classification. The pretrained ConvergeCELL patient representation model and bulk distillation module are publicly available on Hugging Face (huggingface.co/ConvergeBio/virtual-cell-patient) under the Apache 2.0 license. Competing Interest Statement All authors are employees of Converge Bio Ltd. Abbreviation table - AUROC - Area under the receiver operating characteristic curve - BM - Bone marrow - C2S - Cell2Sentence - DE - Differential expression - FDR - False discovery rate - IG - Integrated gradients - SOFA - Sequential Organ Failure Assessment - LLM - Large language model - MCP - Model Context Protocol - MGUS - Monoclonal gammopathy of undetermined significance - MLP - Multi-layer perceptron - MM - Multiple myeloma - MS - Multiple sclerosis - PBMC - Peripheral blood mononuclear cell - PCA - Principal component analysis - PR-AUC - Precision-recall area under the curve - T4 - CD4+T - PC - Plasma cells - PReLU - Parametric rectified linear unit - QC - Quality control - ROC - Receiver operating characteristic

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00